Patent · US Active

Compounds that inhibit MCL-1 protein

US10300075B2 · kind B2 · utility

5Cited by

5References

39Claims

0Family size

Assignee

AMGEN INC. · US

Inventors

Sean P. Brown · Craydon Court, US
Kexue Li · Newbury Park, US
Yunxiao Li · Sunnyvale, US
Markian Stec · Thousand Oaks, US

Key dates

Filing date	Mar 28, 2018
Grant date	May 28, 2019
Priority date	—
Expiry date	Mar 28, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D498/08
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.